bioavailabilities were 94, 88.89 and 83.63 for zinc aspirin; aspirin lysinate and aspirin respectively. The peak plasma concentration (C max ) were 54. 5188, 50.271.68 and 48.091.15 ugl -1 for zinc aspirin, aspirin lysinate and aspirin, respectively. There was significant difference in the t max . The area under the plasma concentration-time curve (AUC) values were 148. 932.79, 140.832.3 and 132.493.56 ug.h/ml for zinc aspirin, aspirin lysinate and aspirin, respectively. There were significant differences in the C max , t max and AUC following oral administration. The anti-inflammatory and analgesic studies revealed that zinc aspirin administered rectally or orally was more effective as anti-inflammatory and analgesic. The invivo studies were correlated with the in-vitro release studies of aspirin from the prepared suppositories.Based on the obtained results, the authors recommend the possible use of zinc aspirin as a substitute of aspirin containing products.